The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...
Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with exclusions minimizing confounding from comorbid hematologic, renal, infectious ...
Uptake of sodium-glucose cotransporter 2 (SGLT2) inhibitors among US patients eligible for treatment according to clinical guidelines is extremely low, no matter their diabetes status, according to ...
Sotagliflozin (Inpefa; Lexicon Pharmaceuticals), a dual sodium-glucose co-transporter 1/2 inhibitor, appears to reduce both MACE and stroke risk among patients with type 2 diabetes, chronic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results